|Videos|September 28, 2022
Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy
Author(s)Ajay K. Nooka, MD, Matthew James Pianko, MD
Drs Nooka and Pianko discuss how they measure a successful treatment response in patients with transplant-eligible multiple myeloma after induction therapy.
Advertisement
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5